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Abstract—Botulinum neurotoxins (BoNTs) are the most potent of the known biological toxins, and consequently are listed as category A biowarfare agents. Currently, the only treatments against BoNTs include preventative antitoxins and long-term supportive
care. Consequently, there is an urgent need for therapeutics to counter these enzymes––post exposure. In a previous study, we identiﬁed a number of small, nonpeptidic lead inhibitors of BoNT serotype A light chain (BoNT/A LC) metalloprotease activity, and we
identiﬁed a common pharmacophore for these molecules. In this study, we have focused on how the dynamic movement of amino
acid residues in and surrounding the substrate binding cleft of the BoNT/A LC might aﬀect inhibitor binding modes. The X-ray
crystal structures of two BoNT/A LCs (PDB refcodes = 3BTA and 1E1H) were examined. Results from these analyses indicate that
the core structural features of the examined BoNT/A LCs, including a-helices and b-sheets, remained relatively unchanged during
1 ns dynamics trajectories. However, conformational ﬂexibility was observed in surface loops bordering the substrate binding clefts
in both examined structures. Our analyses indicate that these loops may possess the ability to decrease the solvent accessibility of the
substrate binding cleft, while at the same time creating new residue contacts for the inhibitors. Loop movements and conformational/positional analyses of residues within the substrate binding cleft are discussed with respect to BoNT/A LC inhibitor binding
and our common pharmacophore for inhibition. The results from these studies may aid in the future identiﬁcation/development of
more potent small molecule inhibitors that take advantage of new binding contacts in the BoNT/A LC.
Published by Elsevier Ltd.

1. Introduction
Botulinum neurotoxins (BoNTs) are secreted by anaerobic spore-forming bacteria Clostridium botulinum, and
are the most poisonous of known biological substances.1
It is estimated that the lethal intravenous dose of BoNT
Abbreviations: BoNT, botulinum neurotoxin; BoNT/A, botulinum
neurotoxin serotype A; BoNT/B, botulinum neurotoxin serotype B;
LC, light chain; HC, heavy chain; Rmsd, rms deviation.
Keywords: Bioterrorism; Botulinum neurotoxin; Drug discovery; Inhibitors; Molecular dynamics; Molecular modeling; Pharmacophore;
Metalloprotease.
* Corresponding authors. Tel.: +1 301 846 5791; fax: +1 301 846 6106
(R.G.); tel.: +1 301 619 4246; fax: +1 301 619 2348 (S.B.); e-mail
addresses: gussio@ncifcrf.gov; sina.bavari@amedd.army.mil
0968-0896/$ - see front matter Published by Elsevier Ltd.
doi:10.1016/j.bmc.2004.10.026

serotype A (BoNT/A) in humans is 1–5 ng kg1.2,3
Annually, numerous cases of accidental BoNT poisoning are reported in both humans and animals.1 Furthermore, as BoNTs continue to gain popularity as: (1)
therapies for muscle hyperactivity and spasticity4–7 and
(2) preferred agents for a range of cosmetic applications,8–10 inadvertent overdosing (requiring immediate
toxin inhibition) may become problematic. More ominous is the fact that BoNTs have been weaponized in
highly toxic aerosol form, and malevolent airborne
release and/or food contamination pose a signiﬁcant
threat to both civilians and military personnel.2,11 In
light of the lethality of BoNTs, and the longevity of
the paralysis induced by these enzymes,12 there is a
pressing need for a better understanding of how inhibitors might interact with these toxins.
This article is a U.S. government work, and is not subject to copyright in the United States.
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BoNTs are composed of a heavy chain (HC) (100 kDa)
and a light chain (LC) (50 kDa), which are linked by a
disulﬁde bridge.13 The HC is responsible for: (1) binding
to surface receptors on cholinergic nerve terminals; (2)
plasma membrane penetration via receptor mediated
endocytosis; and (3) toxin release into the nerve cytosol.14,15 For BoNT/A, a protective belt extending from
the translocation domain of the HC wraps around the
LC and shields the substrate binding cleft prior to neuronal internalization.16 The LC (also referred to as the
catalytic domain) separates from the HC under the
low pH conditions of the endosome, and acts as a zinc
metalloprotease that cleaves SNARE (soluble NSF–ethylmaleimide-sensitive factor attachment protein receptor) proteins.14,15 SNARE proteins are involved in
membrane fusion and the exocytosis of neurotransmitter
containing vesicles.17 BoNT serotypes A and E cleave
SNAP-25
(synaptosomal-associated
protein
of
25 kDa),18 serotypes B, D, F, and G cleave VAMP (vesicle-associated membrane protein) or synaptobrevin,19–22
and serotype C1 cleaves both SNAP-25 and syntaxin
1.23 Following BoNT LC mediated cleavage of SNARE
proteins, acetylcholine release into neuromuscular synapses is compromised, and paralysis ensues.
In a recent report,24 we identiﬁed novel, small (nonpeptidic) molecule leads that inhibit BoNT/A LC metalloprotease activity by up to 62% at 20 lM
concentrations, and we developed a common pharmacophore for these inhibitors based on conformational
analyses and molecular docking studies24 (Fig. 1 shows
the two-dimensional structures of two of the most potent of these inhibitors, which will be referred to in the
text). In this study, we used molecular dynamics to explore how the motion of residues in and around the
BoNT/A LC substrate binding cleft might aﬀect inhibitor binding. In general, the reported analyses support
the crystallographically determined structures of
BoNT/A LCs that were obtained from the holotoxin
(PDB refcode = 3BTA)16 and PDB refcode = 1E1H
(two LCs engaged in intermolecular autocatalysis)25––
a-helices and b-sheets remained stable over the course
of the dynamics simulations. However, our results do
suggest that surface loops13,16,25 may reorient to par-

Figure 1. Two-dimensional structures of BoNT/A LC metalloprotease
inhibitors michellamine B and Q2-15. Michellamine B potency: 62%
inhibition at 20 lM concn; Q2-15 potency: 60% inhibition at 20 lM
concn.

tially shield the substrate binding cleft following LC release from the HC, and that these loop movements may
create new binding surfaces for inhibitors, and/or facilitate inhibitor desolvation. Molecular docking studies
using previously identiﬁed small molecule inhibitors of
BoNT/A LC metalloprotease activity24 have been used
to reﬁne our common pharmacophore.24
2. Methods
2.1. Molecular modeling
The BoNT/A holotoxin X-ray structure (PDB code =
3BTA16) includes both the HC and the LC. First, the
HC, which is composed of the translocation domain
(residues A448–A872) and the receptor binding domain
(residues A873–A1295), was removed from the structure, as: (1) access to the substrate binding cleft of the
BoNT/A is completely blocked by the protective belt
of the HC;13,16 (2) it is the reduced form of this enzyme
(i.e., the disulﬁde bridge connecting the HC and the LC
is broken) that displays peptidase activity;19,26 and (3)
the BoNT/A LC alone (i.e., without the HC component)
is active.25,27 Hydrogens were added to the LC (residues
A1–A415, which are complementary to the residues of
the 1E1H BoNT/A LC structure (see below),25) and
the structure was energy reﬁned using the DISCOVER
(Accelrys, San Diego, CA) programÕs cﬀ91 force ﬁeld.
The zinc ion, and coordinating residues (H222, E223,
H226, and E261) were ﬁxed to their original crystallographic coordinates. The molecular mechanics energy
reﬁnement involved applying 2000 kcal/mol per Å2 of
force that was stepped oﬀ the structure in 100 kcal/mol
decrements by minimizing with conjugate gradients until
the norm of the gradient was 0.01 kcal/Å2.28,29 The coordinates of the energy-reﬁned model were within the
experimentally determined X-ray crystallographic resolution, and were used as a starting point for molecular
dynamics simulations.
Molecular dynamics were performed using DISCOVER
3.0, and involved 200 ps of direct velocity scaling (cﬀ91
force ﬁeld, distance dependent dielectric, 0.5 fs time step,
initial temperature = 10 K, ﬁnal temperature = 300 K),
followed by dynamics using the Berendsen method of
temperature-bath coupling (0.5 fs time step; 300 K) to
1 ns. Initially, at least 100 lowest energy structures and
10 highest energy structures were used to analyze
BoNT/A LC conformers collected over the course of
the dynamics simulation.
The X-ray structure PDB code = 1E1H25 is composed of
two LCs engaged in the intermolecular autocatalysis of
a peptide bond located in corresponding loops (composed of residues 232–258). For these studies, one of
the LCs and all water molecules were removed from
the X-ray crystal structure; the LC composed of residues
A7–A249 and B251–B415 was chosen for dynamics
simulations. Several residues were missing from surface
loops of the crystal structure: L199, E200, V201,
D202, T203, N204, P205, L206, Y250, and N393. These
missing residues were built into the structure using
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corresponding residues in the 3BTA BoNT/A LC as
templates. Following, hydrogens were added and the
1E1H BoNT/A LC was subjected to the same molecular
mechanics and molecular dynamics protocols as described for the 3BTA BoNT/A LC (see above). At least
100 lowest energy structures and 10 highest energy structures from the dynamics trajectory were used to analyze
conformers of this BoNT/A LC.
Inhibitors were docked by combining molecular
mechanics minimizations with the hydropathic scoring
function HINT (eduSoft, Richmond, VA) in an iterative
manner to achieve optimal complementarity with
BoNT/A LC substrate binding clefts.28,29 With regard
to BoNT/A LC dynamics structures, 3BTA structures
collected up to 225 ps following trajectory equilibration
were found to possess suitable complimentary for michellamine B docking; for 1E1H, structures collected up
to 205 ps following trajectory equilibration were found
to possess suitable complementarity for docking Q215. Lowest energy structures from these trajectory
ranges were subsequently used in the docking studies.
For 3BTA, this corresponded to a structure collected
at 188.5 ps; for 1E1H this corresponded to a structure
collected at 123.5 ps. These two structures were reﬁned
with molecular mechanics as described above. Following, compounds were manually docked into the BoNT/
A LC substrate binding clefts of the indicated dynamics
models, as well as the molecular mechanics ÔonlyÕ reﬁned
X-ray crystal structures, and van der Waals violations
P0.25 Å were removed by small adjustments to inhibitor positioning and enzyme side-chain torsion angles.
The inhibitor–enzyme structure coordinates were minimized in the same manner as described above, and were
subjected to hydropathic analyses, using the program
HINT ,
to eliminate/reduce unfavorable contacts.
Coordinates for the docked models are available upon
request.

3.1. Comparisons of BoNT/A LCs following dynamics
simulations
Two BoNT/A LC structures were examined. One
BoNT/A LC was taken from the X-ray crystal structure
of the holotoxin (PDB refcode = 3BTA;16) the other was
obtained from a recently released X-ray crystal structure
of two LCs engaged in intermolecular autocatalysis
(PDB refcode = 1E1H.25) With regard to the dimeric
1E1H X-ray crystal structure, BoNT/A LC autocatalysis has been observed in solution, and may occur via
an intermolecular route.32,33 Hence, these atomic coordinates25 provide evidence to structurally explain a
mechanism of intermolecular BoNT/A LC autocatalysis.25,32,33
Following the dynamics simulations, analyses of at least
100 lowest-energy and 10 highest-energy structures from
the trajectories of both BoNT/A LCs did not reveal the
existence of signiﬁcantly diﬀerent conformations of this
enzyme (Table 1). For example, individual superimpositions across all backbone atoms of each of the 100 lowest-energy conformers from the dynamics trajectory
of the 3BTA BoNT/A LC with that of the average
structure (from the same trajectory) resulted in a mean
Table 1. Comparisons of BoNT/A LC models

3BTA
Crystal versus
dynamics avg.
Dynamics avg.
versus 100 L.E confs.b
Dynamics avg.
versus 10 H.E. confs.c

Michellamine B (Fig. 1)24 was obtained from the
National Cancer Institute, and Q2-15 (Fig. 1)24 was
obtained from Dr. Jonathan Vennerstrom, University
of Nebraska Medical Center. The HPLC based assay
used to quantitate BoNT/A LC inhibition has been
described in detail elsewhere.30,31

a

All (Å)

Loops 1–3 Only a-helices
omitted (Å) and b-sheets (Å)

4.0

2.7

1.8

2.4

1.8

1.1
2.4

0.57
1.7

0.76d
0.86e

1E1H
Crystal versus
dynamics avg.
Dynamics avg.
versus 100 L.E confs.
Dynamics avg. versus
10 H.E. confs.

0.71f

3BTA versus 1E1H
Crystal versus crystal
Dynamics avg. versus
dynamics avg.

2.2
3.8

3.8

0.73g

All superimpositions were performed using backbone atoms.
L.E. confs. = lowest-energy conformers from the trajectory.
c
H.E. confs. = highest-energy conformers from the trajectory.
d
The average rmsd for 100 L.E. confs. from the 3BTA dynamics
trajectory compared with the average structure from the same trajectory (rmsd range = 0.64–0.94 Å).
e
The average rmsd for 10 H.E. confs. from the 3BTA dynamics trajectory compared with the average structure from the same trajectory
(rmsd range = 0.70–0.99 Å).
f
The average rmsd for 100 L.E. confs. from the 1E1H dynamics trajectory compared with the average structure from the same trajectory
(rmsd range = 0.61–0.94 Å).
g
The average rmsd for 10 H.E. confs. from the 1E1H dynamics trajectory compared with the average structure from the same trajectory
(rmsd range = 0.63–0.79 Å).
b

Molecular dynamics simulations were used to evaluate
BoNT/A LC conformations at 300 K over 1 ns. These
studies were initiated to answer the following question:
how might residue movements in and around the
BoNT/A LC substrate binding cleft aﬀect predicted
inhibitor binding modes,24 and how might this information be used to reﬁne the common pharmacophore for
BoNT/A LC inhibitors?24 Answers to this question will
provide important information for ongoing studies to
develop our lead inhibitors into therapeutically viable
countermeasures against BoNT/A LC metalloprotease
activity.

Rmsda

BoNT/A LC structures

2.2. Compound information and HPLC-based assay

3. Results and discussion
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Figure 2. Comparisons of BoNT/A LC models. (a) All backbone atoms superimposition of the BoNT/A LCs from X-ray crystal structures PDB
refcodes = 3BTA (red) and 1E1H (blue); (b) all backbone atoms superimposition of the 3BTA BoNT/A LC X-ray crystal structure (green) and its
dynamics average structure (magenta). Loops 1–3 are shown as ribbons; (c) all backbone atoms superimposition of the 1E1H BoNT/A LC X-ray
crystal structure (green) and its dynamics average structure (magenta). Loops 1–3 are shown as ribbons.

rmsd of only 0.76 Å (range = 0.61–1.0 Å), with a standard deviation of 0.95 Å (Table 1). Comparable results
were obtained when comparing lowest-energy conformers from the dynamics simulation of the 1E1H
BoNT/A LC with the average structure from its trajectory (Table 1). Additionally, the secondary structures
(i.e., a-helices and b-sheets) of the 3BTA and 1E1H
BoNT/A LC X-ray structures were nearly identical
(Fig. 2a), and remained so throughout these analyses
(Table 1).
3.2. BoNT/A LC surface loop movements
In contrast, the molecular dynamics studies did provide
evidence that surface loops bordering the substrate
binding clefts of the examined BoNT/A LCs possess
the ability to undergo movement that may be important
for optimizing inhibitor binding. The surface loops,13,25
referred to as: loop 1 (residues 48–78); loop 2 (residues
167–180); and loop 3 (residues 232–258) for the remainder of the text (Fig. 2b and c), were the main contributors to conformational diﬀerences between average
structures obtained from the dynamics simulations and
original X-ray crystallographic structures (Table 1). In
accordance with these results, B-factors for residues
forming a-helices and b-sheets, which remained stable
over time (as described above, Table 1), possess, in general, greater thermodynamically stability than residues
in the indicated loops. Furthermore, the observed loop
movements in both LC structures, which were solved
under diﬀerent crystallographic conditions, were very
similar in nature. Segelke et al.25 and Lacy and Stevens13
have suggested that conformational changes in surface
loops, which are also found in BoNT/B LC X-ray structures,34,35 may impact substrate recognition/binding
and/or catalysis. The fact that our analyses indicate
the possibility of conformational changes in these loops
supports their hypotheses.
Observed loop 1 (residues 48–78) movements during
dynamics simulations indicated that this structural feature may play an important role in inhibitor binding
(Fig. 2b and c). Interestingly, during the dynamics simu-

lations of both the 3BTA and the 1E1H BoNT/A LCs,
loop 1 possessed the ability to move toward and partially into the substrate binding clefts. Furthermore, it
should be noted that the intermolecular lysis observed
in the 1E1H structure did not impact loop 1Õs position
in the X-ray crystal structure, and therefore would probably not play a signiﬁcant role in predetermining the
position of this loop.
Taking this information into consideration, the examined BoNT/A LC dynamics trajectories may provide
snapshots of possible loop 1 movement. Speciﬁcally,
the two X-ray crystal structures show loop 1 in a more
ÔopenÕ conformation, allowing for unimpeded access to
a solvent exposed cleft; however, dynamics simulations
appear to indicate that the natural movement of loop
1 may allow it to reorient toward the LC substrate binding cleft, and it is this relatively more ÔclosedÕ conformation that may present additional enzyme contacts that
facilitate inhibitor or substrate binding. At the same
time, loop 1 movement partially shields the cleft from
the solvent interface, which might aid the catalytic process. Future docking studies of the most potent BoNT/A
LC inhibitor to date (a pseudo-peptide possessing a terminal 3-phenyl-2-thiol-propionyl attached via an amide
bond to the N-terminus of RATKML (Ki = 300 nM),36)
and a rationalization of the SAR that accompanies this
inhibitor,36 would help to clarify which conformation of
the enzyme may be the active form.
Loop 2 (residues 167–180) in the X-ray structure of the
3BTA LC is oriented away from the substrate binding
cleft––due to the presence of residues from the translocation domain protective belt (Fig. 2b). In the absence
of the protective belt, this loop adopted a new conformation (i.e., during the dynamics simulations) that
brought it into closer association with the substrate
binding cleft. Similar orientation of loop 2 toward the
substrate binding cleft was also observed for the 1E1H
LC (Fig. 2c). However, loop 2 in the 1E1H X-ray structure was positioned in such a way that it was already oriented toward the substrate binding cleft (as opposed to
this loop in the 3BTA BoNT/A LC x-ray structure), thus
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providing further evidence that this loop is in closer
association with the substrate binding cleft.
Loop 2 orientation toward the substrate binding cleft
may: (1) provide additional ligand contacts and (2) decrease binding cleft solvent accessibility, which would
reinforce inhibitor/substrate binding by creating a more
favorable environment for desolvation. Indeed, it is possible that the combined movements of both loop 1 and
loop 2 help induce the required conformation of the
(otherwise ﬂexible) substrate, SNAP 25, which is necessary for optimal binding. From a teleological perspective, perhaps taking advantage of such surface loop
movements may have facilitated the evolution of highly
toxic and substrate speciﬁc BoNT serotypes from a common ancestor.
Loop 3 (residues 232–258) movement during dynamics
simulations of both examined BoNT/A LCs did not affect accessibility to the enzymesÕ substrate binding clefts.
Both the 3BTA LC loop 3 and the 1E1H LC loop 3 collapsed toward space on the enzymeÕs surface (Fig. 2b
and c) that was originally occupied by either: (1) the
holotoxin translocation domain and its protective belt
component (in the case of the 3BTA BoNT/A LC) or
(2) the loop 3 of the opposing LC in the dimeric structure (in the case of the 1E1H BoNT/A LC).
3.3. Loop movements and BoNT/A LC inhibitor binding
In a previous report,24 molecular docking studies were
used to deﬁne three regions in the BoNT/A LC substrate
binding cleft that are hypothesized to be contact subsites
for identiﬁed BoNT/A LC inhibitors. These regions included hydrophobic binding subsite 1 (composed of resi-
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dues F162, F177, F193, and T219), binding subsite 2
(composed of residues C164, T175, H226, R230, P238,
and E260), and a more loosely organized polar contact
region (composed of residues E55, Q161, E163, K165,
and R176). During these earlier studies, a molecular
mechanics reﬁned BoNT/A LC from the 3BTA X-ray
crystal structure served as the toxin model.24 Observed
reorientations of BoNT/A LC surface loops bordering
the enzymeÕs substrate binding cleft (during dynamics
simulations) are now considered with respect to previously speciﬁed inhibitor contact subsites in both the
3BTA and the 1E1H BoNT/A LC models.
The composition of binding subsite 1 (also referred to as
the S01 binding site25,36) remained relatively unchanged
during the dynamics simulations, as examination of
structures from the dynamics trajectories of both the
3BTA LC and the 1E1H LC showed that previously
identiﬁed residues: F162, F187, F193, and T21924 composed this subsite consistently over time. Consequently,
binding subsite 1 is a stable pocket where hydrophobic
collapse between the enzyme and moieties from our
inhibitors, such as a chloro, methyl, methoxy, or a dihydro imidazolyl, is likely to occur.24 For example, when
one of our previously identiﬁed inhibitors, Q2-15 (Fig.
1) (60% inhibition at 20 lM concn),24 is docked into
either a structure from the 1E1H BoNT/A LC dynamics
trajectory (a low energy structure obtained at 123.5 ps
following trajectory equilibration), or the mechanics
reﬁned X-ray structure of 1E1H, one of the chloro substituents engages in favorable contacts with the hydrophobic side chains of residues in subsite 1 (Fig. 3a and
b). At the same time, the accompanying quinoline nitrogen is in close proximity to the enzymeÕs catalytic engine,
where it is positioned such that it may either engage in a

Figure 3. (a) BoNT/A LC inhibitor Q2-15 docked in the molecular dynamics model for the 1E1H BoNT/A LC. Enzyme atom colors: subsite 1
carbons (light blue); subsite 2 carbons (magenta); polar contact region carbons (orange); all other carbons (green); oxygen (red); nitrogen (blue);
sulfur (yellow). Q2-15 carbons are white and chlorine atoms are light green. BoNT/A LC loops 1, 2, and 3, as well as the side chains of speciﬁed
residues of these loops are shown in thicker stick. Residues with brown stripes are new contacts that are observed when docking Q2-15 in the
dynamics BoNT/A LC (as opposed to contacts made by Q2-15 docked in the molecular mechanics reﬁned X-ray structure); (b) BoNT/A LC inhibitor
Q2-15 docked in the molecular mechanics reﬁned X-ray crystal structure of the 1E1H BoNT/A LC. All colors and stick thickness are as described for
(a). A comparison of (a) and (b) shows how loop 1 reorientation provides additional contacts for the inhibitor.
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direct interaction with the zinc ion, or displace the
engineÕs catalytic water. In a similar manner, Figure 4a
and b show how the methoxy and methyl substituents
of michellamine B (Fig. 1) (62% inhibition at 20 lM
concn) naphthalene ring A engage in favorable hydrophobic interactions with residues of binding subsite 1
in both a structure from the 3BTA dynamics simulation
(a low energy structure obtained at 188.5 ps following
trajectory equilibration) and the mechanics reﬁned
X-ray structure of 3BTA, respectively. Additionally, as
observed for the quinoline nitrogen of Q2-15, the
hydroxyl moiety of naphthalene ring A is positioned
such that it may interact directly with the enzymeÕs catalytic zinc, or displace the water that is used by the
enzymeÕs catalytic engine.
The binding mode of Q2-15 in the dynamics structure of
1E1H (Figure 3a) also shows that loop 1 orientation toward the enzymeÕs substrate binding cleft creates a new
hydrophobic pocket near subsite 1 (composed of residues K65 (hydrophobic side chain), V67, and P68),
which provides a complimentary binding surface for
three methylene carbons that form half of the ﬂexible
linker connecting the inhibitorÕs two 7-chloroquinoline
components (Fig. 3a). These additional hydrophobic
contacts are not observed when Q2-15 is docked in the
more ÔopenÕ mechanics reﬁned structure (Fig. 3b). In like
manner, michellamine B binding in the 3BTA dynamics
structure (Fig. 4a) shows the methyl substituent of naphthalene ring A engaging in a hydrophobic contact with
V67 (this contact is not observed when michellamine B
is docked in the 3BTA mechanics reﬁned structure
(Fig. 4b)).
The solvent accessibility of binding subsite 2 is reduced
during the dynamics simulation of the 3BTA structure––
due to loop 2 movement (as indicated above, loop 2 was

already oriented toward the substrate binding cleft in
the 1E1H X-ray crystal structure). However, these
changes had little aﬀect on the amino acids composing
this subsite: C164, H226, R230, E260, and P238 remained key residues surrounding this pocket. Figure
3a and b show how Q2-15 binding within this subsite
is very similar in both the 1E1H dynamics structure
and the 1E1H mechanics reﬁned X-ray structure, respectively. Speciﬁcally,the other Q2-15 chloroquinoline moiety docks in this subsite in such a way that the quinoline
ring sits in close proximity to the side chain of R230
(with the quinoline nitrogen pointed toward that solvent
interface), while the 7-chloro substituent of this moiety
points into the binding subsite and engages in favorable
hydrophobic contacts with the side-chain imidazole of
H226 and the side-chain methylenes of E260.
Loop 2 reorientation is more dramatic when comparing
michellamine B docked in the 3BTA dynamics structure
(Fig. 4a) and the mechanics reﬁned structure (Fig. 4b).
Figure 4a shows how loop 2 reorientation increases
the depth of this subsite––compared to the crystal structure (Fig. 4b)––with the entire loop rising as it moved toward the enzymeÕs binding cleft. As a result, a new
boundary for this end of the substrate binding pocket
is created, and solvent accessibility is reduced. With regard to michellamine B binding in subsite 2, the methoxy substituent of naphthalene ring B packs into space
located behind H226 (in a manner similar to one of
the chloro substituents of Q2-15) in both the 3BTA
dynamics structure and the mechanics reﬁned X-ray
crystal structure. In contrast, the methyl substituent on
naphthalene ring B in the dynamics structure sits behind
loop 2 and engages in hydrophobic contacts with the
side-chain methylenes of residue E170 (Fig. 4a), while
this same substituent in the molecular mechanics reﬁned
structure of 3BTA is more solvent exposed (Fig. 4b).

Figure 4. (a) Michellamine B docked in the molecular dynamics structure for the 3BTA BoNT/A LC. All colors and stick thickness are as described
in the caption for Figure 3a; (b) michellamine B docked in the molecular mechanics reﬁned X-ray crystal structure of the 3BTA BoNT/A LC. All
colors and stick thickness are the same as described in Figure 3a. A comparison of (a) and (b) shows that their are more favorable electrostatic and
hydrophobic contacts between michellamine B and the BoNT/A LC dynamics structure, and that these interactions are the result of loop
reorientations toward the substrate binding cleft.
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Residues in the previously identiﬁed polar contact region (composed of residues E55, Q161, E163, K165,
and R17624) for inhibitors also remained consistent over
the course of the dynamics trajectory. However, loop 1
reorientation partially covers this contact region, leaving
it less solvent accessible, and also brings new contact residues into association with this binding region.
Models of Q2-15 docked in both the BoNT/A LC
dynamics structure (Fig. 3a) and the mechanics reﬁned
X-ray structure (Fig. 3b) indicate that the inhibitors
ionizable secondary nitrogen engages in a hydrogen
bond with the side-chain carboxylate of E163. Furthermore, due to loop 1 reorientation in the dynamics structure, the inhibitorÕs secondary nitrogen also engages in
an ion-dipole interaction with the backbone carbonyl
of K65 (Fig. 3a). For comparison, the ionizable nitrogen
of the michellamine B tetrahydro-isoquinoline moiety
attached to naphthalene ring B engages in a hydrogen
bond with the side-chain carboxylate of residue E55,
and is also in close proximity to the side chain carboxylate of E163, in both the dynamics and molecular
mechanics reﬁned models of 3BTA. Furthermore, in
the 3BTA dynamics structure (Fig. 4a), loop 1 reorientation resulted in additional residue contacts with the 1,3dimethyl-1,2,3,4-tetrahydro-isoquinoline-6,8-diol moiety attached to naphthalene ring B. Speciﬁcally, the
side-chain carboxylate of E63 is located near the ionizable nitrogen of the 1,3-dimethyl-1,2,3,4-tetrahydro-isoquinoline-6,8-diol moiety, and engages in a hydrogen
bond with the 8-hydroxyl substituent, while the moieties
3-methyl substituent engages in a hydrophobic interaction with the P61 pyrrolidine (Fig. 4a).
In general, Q2-15 and michellamine B, although structurally very diﬀerent, engage in similar contacts in the
BoNT/A LC substrate binding cleft––regardless of the
enzyme model that is used. These two compounds also
share comparable pharmacophoric features,24 which
would seem to explain their comparable inhibitory potency. Furthermore, analyses of inhibitors docked in
the dynamics structures, versus mechanics reﬁned Xray crystal structures of both 1E1H and 3BTA, indicate
that the models obtained from the dynamics simulations
provide additional inhibitor contacts that may be
important for inhibitor binding. In particular, additional hydrophobic contacts near subsite 1, additional
contacts at the polar contact region, and a reduction
in the solvent accessibility at subsite 2 (following loop
2 reorientation toward the substrate binding cleft) all
seem to suggest that possible loop reorientations toward
the BoNT/A LC substrate binding cleft may be important for understanding inhibitor/substrate binding, and
consequently, for the future development of small molecule inhibitors.
3.4. Potential silver ion binding sites
We have also reported that silver ion inhibits BoNT/A
LC metalloprotease activity (100% inhibition at
P5 lM) without displacing the catalytic zinc ion or
causing enzyme denaturation.24 Observed loop 1 movement toward the substrate binding cleft may aid in par-

Figure 5. A proposed binding site for silver ion in the dynamics
structure of the 3BTA BoNT/A LC. Oxygen atoms are red and
nitrogen atoms are blue. The silver ion is shown as a light blue sphere
and the zinc ion is a magenta sphere. All other atoms are green. Loops
1, 2, and 3 are shown in thicker stick. Loop 1 reorientation partially
shields the polar contact region from solvent, creating a pocket that
may potentially trap a silver ion.

tially explaining these results. In particular, Figure 5
shows how loop 1 reorientation in the 3BTA dynamics
structure creates a pocket that could potentially trap a
silver ion. In Figure 5, a silver ion is shown engaging
in an ionic interaction with the side-chain carboxylate
of D158, and ion-dipole interactions with the side-chain
amide carbonyl of Q161, and the backbone carbonyl
oxygens of V69 and I160. In addition to the above contacts, the silver ion might also interact with other residues in the polar contact region, including E163. It
should also be noted that binding subsite 2 may provide
a potential silver ion contact region, with the ion coordinated to the C164 side-chain thiol, and engaging in electrostatic interactions with surrounding residues H226
and E260. Interestingly, there are no other regions in
or near the substrate binding cleft that would provide
similar clusters of residues for silver ion ÔtrappingÕ.
3.5. Reﬁnement of the BoNT/A LC inhibitor
pharmacophore
Figure 6 shows the components of our pharmacophore
for BoNT/A LC inhibition.24 Components A and B in
Figure 6 represent two planar moieties, one of which
contains a heteroatom that may engage in an interaction
with the enzymeÕs catalytic zinc, or potentially replace
the water used by the zinc engine during substrate lysis.
Examples of components A and B include the two-quinoline rings of Q2-15 (Figs. 1 and 3a and b) and the two
naphthalene rings of michellamine B (Figs. 1 and 4a and
b). In Figure 6, pharmacophore components C and D
are two hydrophobic substituents, which are predicted
to interact with subsites 1 and 2 in the substrate binding
cleft, respectively. Examples of components C and D include the two chloro substituents of Q2-15 and the
methoxy substituents (attached to the naphthalene
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These studies have, for the ﬁrst time, used molecular
dynamics to explore conformationally available binding
contacts for our BoNT/A LC inhibitors.24 Results from
dynamics simulations performed on two separate
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4. Conclusions

Table 2. Torsional ranges for potential inhibitor contact residues shown in Figure 6

Comparisons between inhibitors docked in molecular
dynamics models (Figs. 3a and 4a) and inhibitors
docked in molecular mechanics reﬁned models (Figs.
3b and 4b) indicate that inhibitor residue contacts in
binding subsites 1 and 2, and the polar contact region,
remain relatively consistent during the dynamic movement of BoNT/A LC. Moreover, our analyses indicate
that loop reorientations may bring additional residues
into play, which may serve to facilitate inhibitor binding. Based on these observations, the BoNT/A LC inhibitor pharmacophore has been reﬁned via the addition of
residues that are predicted to interact with speciﬁed
pharmacophore components (Fig. 6). Table 2 provides
an overview of the torsional angle ranges of residues
shown in Figure 6. In agreement with comparable dynamic motion observed for the two BoNT/A LCs, torsional ranges for the indicated contact residues also
follow similar trends.

1E1H

rings) of michellamine B. Finally, the polar, ionizable
pharmacophore component E (Fig. 6) is hypothesized
to either engage in electrostatic or water mediated interactions with residues in the polar contact region. Examples of component E include the secondary nitrogen of
Q2-15 and the secondary nitrogen of one of the tetrahydro-isoquinolines of michellamine B.
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Figure 6. Reﬁned pharmacophore for BoNT/A LC inhibition. Planar
components A and B are blue dashed rectangles. The dashed circle in
plane A represents a heteroatom. Hydrophobic components C and D
are shown as light blue circles. The positive ionizable component E of
the pharmacophore is shown as a red circle. Residues that remained
consistent when docking inhibitors in predicted binding subsites of
both dynamics and molecular mechanics ÔonlyÕ reﬁned models are
shown as gray spheres. Residues E63, V67, and E170 are shown as a
gray spheres with dashed black boarders––to indicate that these amino
acids were found to participate when docking inhibitors in dynamics
structures.
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BoNT/A LCs indicated that the a-helices and b-sheets of
this enzyme remain stable over time, but that conformational ﬂexibility in surface loops surrounding the substrate binding cleft may aﬀect inhibitor binding.
Speciﬁcally, our results show that surface loops 1 and
2 may reorient, thereby creating additional residue–
inhibitor contacts, as well as serving to decrease the solvent accessibility of the substrate binding cleft. Finally,
these studies have provided a unique opportunity to
reexamine BoNT/A LC inhibitor binding, and to further
reﬁne a previously proposed pharmacophore for inhibition via the inclusion of potential binding subsite
contacts.

Acknowledgements
The research described herein was sponsored by the US
Army Medical Research and Material Command Research Plan # 02-4-3U-057 and IAA # Y3-CM-100505
(MRMC and NCI). We acknowledge the National Cancer Institute for the allocation of computing time and
staﬀ support at the Advanced Biomedical Computing
Center of the Frederick Cancer Research and Development Center. The contents of this publication do not
necessarily reﬂect the views or policies of the Department of Health and Human Services, nor does the mention of trade names, commercial products, or
organizations imply endorsement by either the US Government or the US Army.

References and notes
1. Foran, P. G.; Davletov, B.; Meunier, F. A. Trends Mol.
Med. 2003, 9, 291.
2. Arnon, S. S.; Schechtler, R.; Inglesby, T. V.; Henderson,
D. A.; Bartlett, J. G.; Ascher, M. S.; Eitzen, E.; Fine, A.
D.; Hauer, J.; Layton, M.; Lillibridge, S.; Osterholm, M.
T.; OÕToole, T.; Parker, G.; Perl, T. M.; Russell, P. K.;
Swerdlow, D. L.; Tonat, K. J. Am. Med. Assoc. 2001, 285,
1059.
3. Rossetto, O.; Seveso, M.; Caccin, P.; Schaivo, G.; Montecucco, C. Toxicon 2001, 39, 27.
4. Gui, D.; Rossi, S.; Runfola, M.; Magalini, S. C. Aliment.
Pharmacol. Ther. 2003, 18, 1.
5. OÕBrien, C. F. Clin. J. Pain 2002, 18, S182.
6. Sheean, G. Curr. Pain Headache Rep. 2002, 6, 460.
7. Kessler, K. R.; Benecke, R. Neurotoxicology 1997, 18, 761.
8. Said, S.; Meshkinpour, A.; Carruthers, A.; Carruthers, J.
Am. J. Clin. Dermatol. 2003, 4, 609.
9. Glogau, R. G. Clin. J. Pain 2002, 18, S191.
10. Sposito, M. M. Plast Reconstr. Surg. 2002, 110, 601.
11. Franz, D. R.; Jahrling, P. B.; Friedlander, A. M.;
McClain, D. J.; Hoover, D. L.; Byrne, W. R.; Pavlin, J.
A.; Christopher, G. W.; Eitzen, E. M., Jr. J. Am. Med.
Assoc. 1997, 278, 399.

341

12. Meunier, F. A.; Lisk, G.; Sesardic, D.; Dolly, J. O. Mol.
Cell. Neurosci. 2003, 22, 454.
13. Lacy, D. B.; Stevens, R. C. J. Mol. Biol. 1999, 291, 1091.
14. Turton, K.; Chaddock, J. A.; Acharya, K. R. Trends
Biochem. Sci. 2002, 27, 552.
15. Singh, B. R. Nat. Struct. Biol. 2000, 7, 617.
16. Lacy, D. B.; Tepp, W.; Cohen, A. C.; DasGupta, B. R.;
Stevens, R. C. Nat. Struct. Biol. 1998, 5, 898.
17. Dolly, O. Headache 2003, 43, S16.
18. Binz, T.; Blasi, J.; Yamasaki, S.; Baumeister, A.; Link, E.;
Sudhof, T. C.; Jahn, R.; Niemann, H. J. Biol. Chem. 1994,
269, 1617.
19. Schiavo, G.; Benfenati, F.; Poulain, B.; Rossetto, O.;
Polverion de Laureto, P.; DasGupta, B. R.; Montecucco,
C. Nature 1992, 359, 832.
20. Schiavo, G.; Rossetto, O.; Catsicas, S.; Polveriono de
Laureto, P.; DasGupta, B. R.; Benfenati, F.; Montecucco,
C. J. Biol. Chem. 1993, 268, 23784.
21. Schiavo, G.; Shone, C. C.; Rossetto, O.; Alexander, F. C.;
Montecucco, C. J. Biol. Chem. 1993, 268, 11516.
22. Schiavo, G.; Malizio, C.; Trimble, W. S.; Polveriono de
Laureto, P.; Milan, G.; Sugiyama, H.; Johnson, E. A.;
Montecucco, C. J. Biol. Chem. 1994, 269, 20213.
23. Blasi, J.; Chapman, E. R.; Yamasaki, S.; Binz, T.;
Niemann, H.; Jahn, R. EMBO J. 1993, 12, 4821.
24. Burnett, J. C.; Schmidt, J. J.; Staﬀord, R. G.; Panchal, R.
G.; Nguyen, T. L.; Hermone, A. R.; Vennerstrom, J. L.;
McGrath, C. F.; Lane, D. J.; Sausville, E. A.; Zaharevitz,
D. W.; Gussio, R.; Bavari, S. Biochem. Biophys. Res.
Commun. 2003, 310, 84.
25. Segelke, B.; Knapp, M.; Kadkhodayan, S.; Balhorn, R.;
Rupp, B. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 6888.
26. Li, L.; Singh, B. R. J. Toxicol., Toxin Rev. 1999, 18, 95.
27. Kadkhodayan, S.; Knapp, M. S.; Schmidt, J. J.; Fabes, S.
E.; Rupp, B.; Balhorn, R. Protein Expr. Purif. 2000, 19,
125.
28. Giannakakou, P.; Gussio, R.; Nogales, E.; Downing, K.
H.; Zaharevitz, D.; Bollbuck, B.; Poy, G.; Sackett, D.;
Nicolaou, K. C.; Fojo, T. Proc. Natl. Acad. Sci. U.S.A.
2000, 97, 2904.
29. Panchal, R. G.; Hermone, A. R.; Nguyen, T. L.; Wong, T.
Y.; Schwarzenbacher, R.; Schmidt, J. J.; Lane, D.;
McGrath, C. F.; Turk, B. E.; Burnett, J. C.; Aman, M.
J.; Little, S.; Sausville, E. A.; Zaharevitz, D. W.; Cantley,
L. C.; Liddington, R. C.; Gussio, R.; Bavari, S. Nat.
Struct. Biol. 2004, 11, 1.
30. Schmidt, J. J.; Staﬀord, R. G. Appl. Environ. Microbiol.
2003, 69, 297.
31. Schmidt, J. J.; Bostian, K. A. J. Protein Chem. 1997, 16,
19.
32. Ahmed, S. A.; Byrne, M. P.; Jensen, M.; Hines, H. B.;
Brueggemann, E.; Smith, L. A. J. Protein Chem. 2001, 20,
221.
33. Ahmed, S. A.; McPhie, P.; Smith, L. A. Biochemistry
2003, 42, 12539.
34. Hanson, M. A.; Stevens, R. C. Nat. Struct. Biol. 2000, 7,
687.
35. Swaminathan, S.; Eswaramoorthy, S. Nat. Struct. Biol.
2000, 7, 693.
36. Schmidt, J. J.; Staﬀord, R. G.; Bostian, K. A. FEBS Lett.
2002, 532, 423.

